A lead candidate psychedelic drug developed by the US company MindMed has shown the potential to treat generalized anxiety disorder in a phase 2b trial.
PureTech Health plc has been awarded $11.4 million (£8.9 million) from the US Department of Defense (DoD) to advance its therapeutic candidate for the potential treatment of neurological and neuropsychiatric disorders.
As part of a new initiative, the generic manufacturer will boost access to treatments for anxiety and depression across seven new states across the US, potentially reaching more than 650,000 uninsured patients.